Vital Therapies, which is developing bio-artificial liver cells for treatment of acute liver failure, raised $54 million by offering 4.5 million shares at $12, below the downwardly revised range of $13 to $15. The company had originally filed to offer 4.4...read more
Vital Therapies, which is developing bio-artificial liver cells for treatment of acute liver failure, lowered the proposed deal size for its upcoming IPO on Monday. The San Diego, CA-based company now plans to raise $63 million by offering 4.5 million shares at...read more
Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18...read more
Vital Therapies prices IPO at $12, below the downwardly revised range
Vital Therapies, which is developing bio-artificial liver cells for treatment of acute liver failure, raised $54 million by offering 4.5 million shares at $12, below the downwardly revised range of $13 to $15. The company had originally filed to offer 4.4...read more
11 US IPOs planned for the week of Apr 14
The following IPOs are expected to price this week: City Office REIT (CIO), a REIT formed to acquire and operate office properties in the US, plans to raise $100 million...read more
Liver disease biotech Vital Therapies decreases range to $13 to $15
Vital Therapies, which is developing bio-artificial liver cells for treatment of acute liver failure, lowered the proposed deal size for its upcoming IPO on Monday. The San Diego, CA-based company now plans to raise $63 million by offering 4.5 million shares at...read more
Liver disease biotech Vital Therapies revives IPO filing, removes original terms
Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18...read more